COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 17 of 552 for:    VANCOMYCIN

Vancomycin Pharmacokinetics in Patients on Peritoneal Dialysis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03685747
Recruitment Status : Recruiting
First Posted : September 26, 2018
Last Update Posted : September 12, 2019
Information provided by (Responsible Party):
Walter K. Kraft, Thomas Jefferson University

Brief Summary:
Vancomycin is the most commonly used empiric treatment for infectious peritonitis in patients on peritoneal dialysis. Current dosing and monitoring for safety and efficacy is empiric, especially for those on rapid-cycling modalities. The goal of this study is to understand the pharmacokinetics of vancomycin in patients on rapid-cycling peritoneal dialysis modalities in order to derive an optimal dosing regimen.

Condition or disease Intervention/treatment Phase
Peritoneal Dialysis-associated Peritonitis Drug: Vancomycin Phase 1

Detailed Description:

Peritoneal dialysis (PD) is a form of renal replacement therapy indicated for those with acute kidney injury or end stage renal disease. Currently, two modalities of PD exist and is individualized based on patient and life-style specific factors. Continuous ambulatory peritoneal dialysis (CAPD) allows 4 - 5 exchanges performed manually whereas automated peritoneal dialysis (APD) involves continuous, automated, cyclical exchanges performed by a device at home during the night. Peritonitis is a common complication in PD and accounts for a large portion of hospital readmission and mortality. Vancomycin is the most common antibiotic recommended and has notable gram-positive coverage used empirically during suspected peritonitis.

Despite widespread use, vancomycin lacks good pharmacokinetic characterization in PD. Early pharmacokinetic studies using vancomycin were conducted predominantly in patients on CAPD on glucose-based prescriptions. Data is non-existent in PD patients administered the novel dialysate solution icodextrin, or those treated with overnight APD. The impact of residual kidney function (RKF) on vancomycin in PD is also lacking. Enhanced vancomycin clearance in RKF may result in under-dosing, while overdosing may result in nephrotoxicity and loss of clinically important RKF.

The investigators will characterize the pharmacokinetic profile of vancomycin following a single intraperitoneal dose of vancomycin in icodextrin dialysate to non-infected PD patients and examine the relationship between RKF and vancomycin clearance using serum, dialysate and urine. The goal is to use this data in non-infected subjects to generate information to guide vancomycin dosing in patients on rapid-cycling PD modalities.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 4 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Prospective, Single-site, Open-label, Pharmacokinetic Study of Intermittent Intraperitoneal Vancomycin in Adult Subjects Receiving Automated Peritoneal Dialysis
Actual Study Start Date : November 15, 2018
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : August 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dialysis

Arm Intervention/treatment
Experimental: Vancomycin
A single 20 mg/kg intraperitoneal dose in 1-liter of 7.5% icodextrin solution of vancomycin will be administered. Sparse blood sampling will be obtained during an overnight 12-hour dwell and during the exchange period.
Drug: Vancomycin
Vancomycin one-time 20 mg/kg intraperitoneal dose.

Primary Outcome Measures :
  1. Maximum total plasma concentration (Cmax) [ Time Frame: Day: 1 ]
    Total systemic plasma concentration following 12-hour dwell

  2. Time to maximum plasma concentration (Tmax) [ Time Frame: Day: 1 ]
    Time (hours) to achieve the maximum plasma concentration

  3. Area under the concentration-time curve (AUC0-T) [ Time Frame: Days: 1-7 ]
    AUC based on vancomycin plasma concentrations

  4. Total body clearance (CLtotal) [ Time Frame: Days: 1-7 ]
    Total vancomycin plasma vancomycin clearance

  5. Dialytic Clearance [ Time Frame: Days: 1-7 ]
    Vancomycin clearance from peritoneal dialysis

Secondary Outcome Measures :
  1. Adverse events [ Time Frame: Days: 1-7 ]
    Any adverse events throughout entirety of study as assessed by physician-investigator

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult male or females between 18 - 85 years old
  • Stabilized on a PD regimen for > 3 months prior to study initiation

Exclusion Criteria:

  • Clinically significant disease unrelated to renal impairment or deemed unfit by the investigator
  • Allergy or hypersensitivity to vancomycin or icodextrin-containing dialysis solution
  • Active peritonitis infection
  • Previous intraperitoneal antibiotic treatment within 2 months
  • Previous intravenous vancomycin treatment within 2 months
  • Hemoglobin < 9 g/dL
  • Pregnant or breast-feeding women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03685747

Layout table for location contacts
Contact: Edwin Lam, PharmD 215-955-9076

Layout table for location information
United States, Pennsylvania
Thomas Jefferson University Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Jingjing Zhang, MD         
Sponsors and Collaborators
Thomas Jefferson University
Layout table for investigator information
Principal Investigator: Walter K Kraft, MD Thomas Jefferson University

Layout table for additonal information
Responsible Party: Walter K. Kraft, Clinical Research Unit Medical Director, Thomas Jefferson University Identifier: NCT03685747    
Other Study ID Numbers: 12451
First Posted: September 26, 2018    Key Record Dates
Last Update Posted: September 12, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Walter K. Kraft, Thomas Jefferson University:
Automated Peritoneal Dialysis
Additional relevant MeSH terms:
Layout table for MeSH terms
Intraabdominal Infections
Peritoneal Diseases
Digestive System Diseases
Anti-Bacterial Agents
Anti-Infective Agents